ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag public outreach immunology microbiology

A silver tree showing roots and branches in a circle on a blue background.
Onward and Upward!
Kristie Nybo, PhD | Sep 8, 2023 | 9 min read
At The Scientist, we are strengthening our roots while reaching for the sky.
The AIDS Research Evaluators
Lynn Gambale | Jul 9, 1995 | 6 min read
Chairman: Arnold Levine, chairman, department of molecular biology, Princeton University Barry Bloom, Weinstock Professor and Howard Hughes Medical Institute (HHMI) investigator, department of microbiology and immunology, Albert Einstein College of Medicine, New York Rebecca Buckley, professor of pediatrics and immunology, Duke University Medical Center Charles Carpenter, chairman, Office of AIDS Research Advisory Committee; professor of medicine,Brown University School of Medicine Don
teacher in front of a classroom
Opinion: Teach Philosophy of Science in High School
Nicholas Friedman and Stephen Esser | Jan 17, 2022 | 4 min read
The pandemic has revealed the importance of preparing students to critically evaluate the conceptual foundations and real-world impact of science.
Bioterrorism Research: New Money, New Anxieties
John Dudley Miller | Apr 6, 2003 | 8 min read
Ned Shaw US scientists have reason to feel both heady and scared. The federal government recently released unprecedented billions of dollars to fund bioterrorism research. Yet, the merits of this sudden shift in focus are being debated, and some worry that the money will be squandered or wasted. "I have been really very upset by the focus on bioterrorism," says Stanley Falkow, professor of microbiology and immunology and of medicine at Stanford University. "Everybody's talking about it, but th
The Search for Persisters
Amanda B. Keener | Aug 11, 2015 | 4 min read
Lyme disease–causing bacteria can outmaneuver antibiotics in vitro and manipulate the mouse immune system.
Opinion: The Zika Effect
Vincent Racaniello | May 27, 2016 | 3 min read
Three reasons why virologists are flocking to study this emerging virus
Contributors
The Scientist | Oct 1, 2016 | 3 min read
Meet some of the people featured in the October 2016 issue of The Scientist
AIDS Investigators Cautiously Applauding Recent Advances
Steven Benowitz | Sep 29, 1996 | 10+ min read
Discoveries announced at conference leave scientists feeling optimistic; yet their enthusiasm is tempered by several persistent concerns. AIDS researchers have many reasons to be encouraged. Studies show that treatments combining new and old drugs can control HIV levels in the blood. Moreover, many scientists and activists note, prevention efforts have helped reduce HIV infection rates. Yet the enthusiasm is tempered by several caveats. Drugs are expensive and have harsh side effects, leading
Human Clinical Trials Begin For Cervical Cancer Vaccines
Steve Bunk | Oct 26, 1997 | 6 min read
Efforts are under way to develop a vaccine against one of the world's deadliest illnesses, cervical cancer. Along with a number of university research laboratories, at least a half-dozen biotechnology and pharmaceutical companies are beginning clinical trials or are in preclinical development of such drugs. Efficacy in humans remains to be firmly established, but if the vaccines progress to later-phase trials, challenging jobs for immunologists, microbiologists, and biochemists will multiply. "
Entrepreneur Opens Clinical Cancer Facility
Robin Eisner | Dec 9, 1990 | 9 min read
Bioscientist Royston turns his attention to creating a center in San Diego's crowded research community Ivor Royston, who at the age of 33 founded Hybritech Inc., the first company in the United States to exploit monoclonal antibodies commercially, and who became a millionaire in the process, is taking his vision for enterprise to a new nonprofit venture. Among the palm trees, a handful of research institutes, and the 90 biotechnology companies that make San Diego an idyllic place for scient

Run a Search

ADVERTISEMENT